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Abstract
Colorectal cancer (CRC) is one the most frequently diagnosed neoplastic diseases worldwide. Currently, aside 
from traditional chemotherapy, advanced CRCs are treated with modern drugs targeting cellular components 
such as epithelial growth factor receptor (EGFR). Since up to 70% of metastasized CRCs are drug resistant, the 
description of recent progress in cellular homeostasis regulation may shed new light on the development of new 
molecular targets in cancer treatment. The Hippo pathway has recently become subject of intense investigations 
since it plays a crucial role in cell proliferation, differentiation, apoptosis and tumourigenesis. Components of 
the Hippo pathway are deregulated in various human malignancies, and expression levels of its major signal 
transducers were proposed as prognostic factors in colorectal cancer. In this review we focused on recent data 
regarding Hippo pathway, its up-stream signals and down-stream effectors. Hippo negatively regulates its ma-
jor effectors, YAP1 and TAZ kinases, which act as transcriptional co-activators inducing expression of genes 
involved not only in tissue repair and proliferation but are also oncoproteins involved in tumour development 
and progression. The deregulation of Hippo pathway components was found in many malignancies.
The interactions between Hippo and Wnt/b-catenin signalling, crucial in the maintenance of cell homeostasis, 
have been described in relation to the control of intestinal stem cell proliferation and CRC development. The 
recently discovered positive feedback loop between activated YAP1 and increased EGFR/KRAS signalling 
found in oesophageal, ovarian and hepatocellular cancer has been related to the CRC progression and resistance 
to EGFR inhibitors during CRC therapy. (Folia Histochemica et Cytobiologica 2015, Vol. 53, No. 2, 105–119)
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Abbreviations: AJ — adherent junction, AMOT — 
angiomotin, APC — adenomatous polyposis coli, 
AREG — amphiregulin, Axl — Axl receptor tyrosine 
kinase, BMI1 — BMI1 polycomb ring finger proto-on-
cogene, β-TrCP — beta-transducin repeat containing 
E3 ubiquitin protein ligase, CK1 — casein kinase 1, 
CRC — colorectal cancer, CTGF — connective tissue 
growth factor, DSS — dextran sodium sulphate, DVL 
— Dishevelled protein, ECM — extracellular matrix, 
EGFR — epithelial growth factor receptor, EMT — 
epithelial-to-mesenchymal transition, FAT — FAT 
atypical cadherin, FZD — Frizzled protein, GPCR 
— G protein coupled receptor, GSK3 — glycogen 
synthase 3, ISC — intestinal stem cell, KO — knock 
out, KRAS — Kirsten rat sarcoma, LATS1/2 — large 
tumor suppressor kinase 1/2, Lgr5 — leucine-rich 
repeat-containing GPCR5, LPR — Lipoprotein 
receptor-related protein, MOB1 — MOB kinase 
activator 1, MST1/2 — serine/threonine kinase 4/3, 
NF2 — neurofibromin 2, Oct-4 — octamer-binding 
transcription factor 4, RASSF — Ras association 
(RalGDS/AF-6) family member, SAV1 — Salvador 
family WW domain containing protein 1, STRIPAK 
— striatin interacting phosphate and kinase complex, 
TAZ — tafazzin, TCF4 — transcription factor 4, 
TEAD — TEA domain family member, TJ — tight 
junction, b-TrCP — b-transducin repeat-containing 
protein, VEGF — vascular endothelial growth factor, 
WB — Western blot technique, YAP1 — Yes-asso-
ciated protein 1
Colorectal cancer
Colorectal cancer (CRC) is the third most commonly 
diagnosed cancer in males and the second in females, 
with an estimated 1.4 million cases and 693,900 deaths 
occurring in 2012 [1]. Five-year relative survival ranges 
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from more than 90% in patients with stage I disease 
to about 10% in patients with stage IV disease [2]. 
Treatment of CRC is one of the most expensive when 
diagnosed at later stages when prognosis is generally 
poor [3]. Although the knowledge of the background 
and the development of CRC has recently increased, 
there is a high need for more studies to found out well 
working prognostic, survival and diagnostic markers. 
Serum markers for routine CRC diagnostic such as CEA 
(carcinoembryonic antigen) and CA 19-9 showed good 
prognostic values and have been used as CRC tumour 
predictors [4]. The aim of this paper was to provide 
rationale to consider the expression of Hippo pathway 
genes as possible new prognostic genes in CRC.
The modern chemotherapy has adapted molecu-
lar findings in many cancers to focus on activation/ 
/inactivation of cancer-related intracellular pathways 
to eliminate or decrease expansion of tumour cells. 
Such drugs which target vascular endothelial growth 
factor-A (VEGF, Bevacizumab) or epidermal growth 
factor receptor (EGFR, Cetuximab and Panitumumab) 
have been introduced for the treatment of CRC [5]. 
However, it was noted that 50–70% of advanced CRC 
cases were resistant to both classical chemotherapeu-
tics and so called biological drugs [6]. In this review 
we also aimed to bring closer the possible associations 
between the Hippo pathway and drug resistance of 
CRC cells.
The Hippo pathway 
The Hippo pathway is an important regulator of cell 
proliferation, growth and apoptosis [7, 8]. Moreover, 
it controls tissue homeostasis, organ size and stem cell 
functions. Its deregulation is frequently observed in 
many human cancers, suggesting that alterations of 
Hippo signalling are connected with tumour initia-
tion and/or progression [9–11]. Hyperactivation of 
the Hippo pathway downstream effectors — YAP1 
(Yes-associated protein 1) and TAZ (transcriptional 
co-activator with PDZ binding motif) may contribute 
to the development of cancer, however, their activa-
tion may also play a positive role in stimulating tissue 
repair and regeneration following injury [12, 13]. 
The general scheme of the Hippo pathway and inter-
actions of mammalian Hippo components with up-
stream signals and effectors are presented in Figure 1 
and listed in Table 1.
Figure 1. The mammalian Hippo pathway. Drosophila orthologue genes are shown below the names of the mammalian 
proteins. When the Hippo pathway is not active (e.g. during cell injury and repair or in cancer), the active effector pro-
teins, YAP1 and TAZ, interact with TEAD1-4 transcription factors and promote transcription of genes involved in cell 
proliferation. During normal cell homeostasis, when the Hippo pathway is active, YAP1 or TAZ are inhibited due to their 
phosphorylation by core components of the Hippo pathway (SAV1, MST 1/2, LATS1/2 — shown in the central rectan-
gle). In a phosphorylated form cytoplasmic YAP1/TAZ may interact with (i) the 14-3-3 protein, (ii) components of cell 
junctional complexes like AMOT or b-catenin, or (iii) may be degraded in proteasomes. YAP1/TAZ can be also regulated 
by other mechanisms such as cell polarity, GPCR signalling or ECM stiffness as described in the body text. Acronyms are 
explained on the first page
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Discovery and function of the Hippo pathway  
in Drosophila
The Hippo pathway was first described almost 20 year 
ago as a result of screening for mutant tumour suppres-
sors in Drosophila. It was found that loss-of-function 
mutation of the Hippo pathway components revealed 
enormous overgrowth of fruit flies as a result of in-
creased cell proliferation and decreased apoptosis [14]. 
The first identified elements of the pathway were its 
core components: warts (wts), hippo (hpo) and salvador 
(sav) (Figure 1) [14–17]. These genes belong to the 
hyperplastic group of Drosophila tumour suppressors, 
wherein mutations of these genes result in robust tissue 
overgrowth without alterations of cell differentiation 
status or cell polarity [18]. Further studies indicated 
that Hpo kinase in association with its adaptor protein 
Sav, phosphorylates and activates complex formed 
by Wts kinase, which is associated with an activating 
subunit Mats [19]. The kinase activity of Hpo could 
be antagonised by dSTRIPAK — phosphatase com- 
plex [20]. The core kinase cassette of the Hippo pathway 
acts as a suppressor of a downstream element — Yorkie 
(Yki) [21]. Subsequent biochemical studies showed 
that Wts directly phosphorylates and inhibits Yki. Yki 
is a transcriptional co-activator that lacks DNA bind-
ing domain. It cooperates with nuclear transcription 
factors, like Scalloped, and enables transcription of 
genes which promote cell proliferation (e.g., Myc) and 
inhibits apoptosis (e.g., diap1) [22, 23]. When the cell 
receives growth inhibiting signals, i.e. due to contact 
inhibition, it activates core components of the pathway 
that phosphorylate Yki. This leads to the cytoplasmic 
sequestration of Yki and its binding to the 14-3-3 pro-
tein, which finally results in Yki protein degradation 
[21, 24]. 
Table 1. Names and main functions of the most important Hippo pathway genes and proteins
Mammalian gene Drosophila gene, protein Protein name, aliases Protein function
NF2 Mer, Merlin Neurofibromin 2, Merlin, ACN,  
SCH, BANF
Signal transduction between cell-membrane 
and cytoskeletal proteins
WWC1 Kibra, ortholog WW and C2 domain containing 1, 
KIBRA, HBEBP3, HBEBP36
Phosphoprotein involved in cell polarity, 
mitosis and cell migration [105]
FRMD6 Ex, Expanded FERM domain containing 6, EX1, 
Willin 
Protein linking cytoskeleton with plasma 
membrane [106]
STK4 Hpo, Hippo Serine/threonine kinase 4,  
MST1, KRS2
Cytoplasmic kinase involved in stress- 
-induced mitogen-activated protein kinase 
cascade
STK3 Serine/threonine kinase 3,  
MST2, KRS1
Kinase activated by proapoptotic molecules 
for the promotion of chromatin condensation 
during apoptosis, cardiomyocyte prolifera-
tion [107], regulation of osteoblast/osteoclast 
differentiation [108]
RASSF1 Ras association (RalGDS/AF-6) 
domain family member 1,  
RASSF1A, NORE2A 
Signal transducer, microtubule stabilization, 
cell cycle arrest [109]
SAV1 Sav, Salvador Salvador family WW domain  
containing protein 1, SAV, WW45
Regulation of protein degradation, RNA 
splicing and DNA transcription
LATS1 Wts, Warts Large tumour suppressor kinase 1, 
WARTS
Serine/threonine kinase involved in mitosis: 
interacts with CDC2/cyclin A
LATS2 Large tumour suppressor kinase 2, 
KPM
Kinase which interacts with centrosomal pro-
teins aurora-a and ajuba during mitosis [110]
MOB1A Mats MOB kinase activator 1A, MOB1, 
MATS, 
Protein involved in mitotic exit network [111], 
microtubule stability control [112]
YAP1 Yki Yes-associated protein 1, YAP, YKI Downstream effector of Hippo pathway 
involved in development, repair and homeo-
stasis
TAZ Tafazzin, EFE, Taz1 Non-specific phospholipid-lysophospholipid 
transacylase involved in cardiolipin  
turnover [113]
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The components and function of the Hippo pathway 
in mammals
The core kinases cassette and downstream effectors of 
the Drosophila Hippo pathway are highly conserved in 
mammals (Figure 1): MST 1/2 (homologues of Hpo), 
SAV1 (Sav homologue), LATS 1/2 (Wts homologues), 
MOB1 (homologues of Mats) and YAP1 and its para-
logue TAZ (homologues of Yki) [25]. It was shown that 
expression of human genes can rescue the phenotypes 
of corresponding Drosophila mutants in vivo [15, 19, 21]. 
The first kinase MST1/2 can be activated in two dif-
ferent ways: (1) by caspase-dependent cleavage under 
apoptotic stress [26], or (2) by binding to one of Ras as-
sociation domain family (RASSF) proteins, RASSF1A 
[27]. Activated MST1/2 interacts with SAV1 through 
the SARAH domains presented on both proteins 
what leads to the phosphorylation and activation of 
their direct substrates LATS1/2 [28]. MOB1 protein 
is also phosphorylated by MST1/2, which results in its 
enhanced interaction with LATS1/2 and formation of 
a complex that phosphorylates and inhibits activity of 
YAP1 and/or TAZ (Figure 1) [28, 29]. 
LATS1/2-dependent phosphorylation of Ser127 
of YAP1 and Ser89 of TAZ in sequences HXRXXS 
(H-histidine; R-arginine; S-serine; X-any amino acid) 
are the most important reactions within this mecha-
nism since this results in binding of 14-3-3 sites and causes 
segregation of YAP1 and TAZ in the cytoplasm [30–32]. 
When LATS1/2 phosphorylates Ser397 of YAP1 and 
Ser311 of TAZ, casein kinase1e/d subsequently phos-
phorylates Ser400 and Ser403 of YAP1 and Ser314 of 
TAZ thereby leading to ubiquitination and degradation 
of YAP1 and TAZ proteins [31]. However, it has to be 
noted that many other kinases, not involved in the Hip-
po pathway, can phosphorylate YAP1 in a specific way, 
depending on the signals received by the cell. Akt kinase, 
a pro-survival kinase, was shown to negatively regulate 
the YAP1-dependent transcription of pro-apoptotic 
genes [31]. It was also found that after DNA damage, 
c-Abl kinase phosphorylates YAP1 at Y407 (tyrosine 
phosphorylation) which enhances the YAP1-p73 inter-
action, prevents Itch-mediated ubiquitination of p73 and 
activates transcription of pro-apoptotic genes [33, 34]. 
Regulation of the YAP1/TAZ activity
Upstream regulators of YAP1/TAZ activity can act 
either through Hippo pathway core components or 
independently of Hippo kinases. For instance, in the 
epithelial cells apical-basal polarity and planar cell 
polarity regulate the Hippo pathway. In Drosophila 
epithelium apically localized Merlin (Mer), Expanded 
(Ex) and Kibra proteins form a complex (Figure 1) 
which acts by binding to Sav, Hpo and Wts to activate 
the Hippo pathway in a cooperative manner or via 
direct binding of Ex and Yki to restrain Yki level in cy-
toplasm and inhibit its transcriptional activity [35, 36]. 
Function of this apical protein complex is con-
served also in mammals. The complex of Nf2 (neurofi-
bromin2, a Mer ortholog), KIBRA and FRMD6 (also 
known as WILLIN, as potential Ex ortholog) inhibits 
YAP1 activity (Figure 1) [37]. Nf2, a tumour sup-
pressor gene is currently the only one known Hippo 
pathway gene that is mutated in cancer (Table 2) [10], 
especially in cancers of central nervous system [38].
Planar cell polarity not only regulates the position 
of a cell in the epithelial layer, but also plays a crucial 
role in the control of development. In Drosophila the 
protocadherins Fat (Ft) and Dachsous (Ds) modulate 
Wts activity; however, the role of their mammalian 
orthologues in the Hippo pathway is not so well un-
derstood and requires further studies [39]. 
Tight junctions (TJ) and adherens junctions 
(AJ) play an important role in intercellular con-
tacts being responsible for the permeability barri-
ers. Structural proteins of TJ and AJ were shown 
to interact with YAP1 (Figure 1). Cytoplasmic 
angiomotin (AMOT) proteins can inhibit YAP1/ 
/TAZ via physical interactions and transfer of 
the YAP1/AMOT complexes from cytoplasm to 
tight junctions or actin cytoskeleton (Figure 1). 
Moreover, AMOT proteins also activate LATS1/2 
to phosphorylate YAP [40]. Another TJ protein, 
ZO-2, was reported to increase nuclear localiza-
tion of YAP and tight junction localization of 
TAZ [41, 42]. It was demonstrated that a-catenin, 
a component of adherens junction, together with 
14-3-3 protein and phosphorylated form of YAP1 
form a complex that inhibits YAP1 activity [43].
It has been shown that YAP1/TAZ activity can 
also depend on environmental cues such as extracel-
lular matrix stiffness, cell tension, cell attachment/ 
/detachment [38, 44]. It was observed, that the nuclear 
localization of YAP/TAZ resulting in TEAD genes’ 
activation was found during proliferation of endothe-
lial and epithelial cells as well as during osteoblast 
differentiation [38]. In breast cancer (MCF10A) and 
mouse fibroblast NIH-3T3 cell cultures it was found 
that YAP1 overexpression and phosphorylation can 
overcome cell contact inhibition [29]. Recent reports 
appraise the role of G protein-coupled receptors 
(GPCRs) and their cooperation with Rho GTPase 
and actin cytoskeleton in negative or positive modi-
fications of YAP1 or TAZ activity. Depending on 
the class of G proteins, but also on the type of their 
ligands, the effects on YAP1/TAZ activity regulation 
might be completely different. For instance, lysophos-
phatidic acid, sphingosine 1-phosphate and peptide 
agonists of thrombin receptors induce, whereas 
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Table 2. The involvement of Hippo pathway proteins in human diseases
Gene’s name Role in human diseases Role in CRC development
NF2, Merlin Mutation leads to neurofibromatosis type II;  
lesions in the CNS and eyes and skin [114, 115]
TSG in some cancers due to mutation  
and underexpression [10]
Barely studied; point mutations were not critical [49]
WWC1, KIBRA Polymorphisms associated with Alzheimer’s  
disease [116]
Not studied
FRMD6, human 
Expanded
Polymorphisms associated with Alzheimer’s disease 
[117], CCL: downregulation leads to resistance  
to Taxol I MC10FA cells [118]
Not studied
STK4, MST1 and 
STK3, MST2 
Phosphorylation β loss of function in prostate cancer 
[119], CCL: overexpression inhibits cell proliferation 
and promote apoptosis in HepG2 cells [87]
Mouse double KO: cholangiocarcinoma [46, 101], 
HCC [120]
Decreased mRNA level in tumour associated with 
node metastasis [121], mouse double KO: crypt  
dysplasia, colon adenoma [46, 78, 120]
RASSF1, RASSF1A TSG: promoter hypermethylation and decrease 
expression in cancer: thyroid [122], oesophageal [123], 
prostate [124], colorectal, breast [125]
TSG; promoter hypermethylation and decrease 
expression in CRC [126, 127]
SAV1, Salvador TSG: LOH and downregulation in renal cell carcino-
ma [128], no gene mutation in stomach, liver and lung 
cancer [129]
CCL: overexpression induces apoptosis in MCF-7 
cells [130]
No gene mutation in CRC [129]
LATS1 TSG: decrease expression in cancer: glioma [131], 
NSLC [132], sarcoma [133] and astrocytoma [134]. 
CCL: LATS1 degradation inhibits apoptosis  
in MCF10A cells [135]
TSG: promoter hypermethylation and mRNA  
decrease in CRC [86]
LATS2 TSG: decrease expression in: malignant mesothelioma 
(and LOH) [136], NSLC (no mutation found) [137] 
and astrocytoma [134]
OG: overexpression in AML [138], nosopharyngeal 
carcinoma [139]
TSG: downregulation in CRC [87]
MOB1, Mob1 Targeted by NS5A protein of hepatitis C virus [140]. 
Mouse KO: various cancer types developed [141]
TSG: downregulation in CRC [142]
TAZ Mutations in Barth syndrome [143]
OG: overexpression in breast cancer [144], HCC [145]
OG: overexpression in CRC [85]
YAP1 OG: overexpression in NSCLC [88], prostate [90], 
breast [91], gallbladder cancer [146] and glioma [89]
TSG: decreased expression in breast cancer [92]
OG: overexpression in CRC [83], in CRC cases  
resistant to cetuximab [102]
TSG: underexpression in CRC [79]
AML — acute myeloid leukaemia; CCL — cancer cell line(s); HCC — hepatocellular carcinoma; KO — knock out; LOH — loss of heterozygosity; 
NSCLC — non-small cell lung cancer; OG — oncogene; TSG — tumour suppressor gene
epinephrine or glucagon repress YAP1/TAZ activity 
[45, 46]. YAP1 could also be regulated by matrix 
stiffness independently from LATS1/2 phosphoryla-
tion. In cells cultured in soft matrix YAP and TAZ 
become phosphorylated even if all known LATS1/2 
phosphorylation-dependent sites in YAP protein are 
inactivated by mutations [47, 48]. 
Hippo pathway cross talk with Wnt/b-catenin 
and EGFR/KRAS signalling
The above presented ways of YAP1/TAZ activity 
regulation show the complexity of molecular inter-
actions within the Hippo pathway. Moreover, cross 
talks of the Hippo pathway with other signalling 
pathways like Notch, EGF or Sonic hedgehog have 
also been described [49]. Due to the space con-
straints they will not be discussed. However, in this 
review we focus on the relationships between Hippo 
and Wnt-b catenin signalling pathways because of 
their crucial role for the maintenance of intestinal 
epithelium homeostasis (Figure 2A). Additionally, 
we will also discuss cross talk between Hippo and 
EGFR/KRAS signalling pathways since their inter-
actions may be involved in drug resistance during 
CRC chemotherapy (Figure 3) [50, 51].
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The interactions of the Hippo  
and Wnt signalling pathways
Organs grow up to pre-defined size and shape, which 
are controlled by different signalling pathways that 
receive external signals and translate them into re-
spective cellular processes. Cell-cell junctions, cell 
adhesion, cell polarity, growth factors or other small 
signalling molecules, like hormones and cytokines, 
control whether a cell should enter process of prolif-
eration, apoptosis or differentiation. Several studies 
have emphasized the critical role of the Wnt/b-catenin 
pathway for gastrointestinal (GI) tract homeostasis. 
Uncovering its interactions with Hippo pathway 
Figure 2. Interactions between Hippo pathway effectors TAZ and YAP and Wnt/b-catenin pathway. A. When Wnt 
pathway is not triggered (WNT OFF), b-catenin and TAZ are inactivated by degradation via destruction complex. When 
Wnt is triggered (WNT ON), e.g. during tissue regeneration, the destruction complex is bound to Wnt/Frizzled and 
LRP5/6 resulting in the inhibition of either b-catenin or TAZ degradation. This leads to the accumulation of b-catenin 
and/or TAZ in the nucleus [38, 57–59]; B. Wnt/b-catenin pathway is restricted by TAZ inhibition. On the contrary,  
YAP1 gene expression is enhanced by b-catenin/TCF4 complex [60]
Figure 3. Indirect relationship between EGFR/KRAS and YAP. A positive autocrine regulation between EGFR and 
YAP1 is established via amphiregulin expression [50, 61]. Cetuximab and Panitumumab are humanized monoclonal  
antibodies against EGFR used in CRC therapy [61]
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increased our understanding of the mechanisms of 
intestinal epithelium homeostasis in physiology and 
pathology [38]. 
The effector of the Wnt signalling (WNTS) path-
way is the transcriptional co-activator b-catenin [52]. 
WNTS ligands include many types of proteins that act 
as morphogens, controlling cell differentiation and 
proliferation. These molecules bind to cell membrane 
receptor complexes composed of Frizzled (FZD) and 
Lipoprotein receptor-related (LPR) proteins and 
thereby regulate the activity of b-catenin [38, 53, 54]. 
b-catenin plays a central role in several developmental 
processes, such as regulation of gene transcription 
[53], stem cell renewal [55] and epithelial-to-mes-
enchymal transition (EMT) [56]. When a cell does 
not receive WNT signals, b-catenin is maintained at 
low level in the cytoplasm through its degradation 
in AXIN destruction complex. This complex is com-
posed of the scaffolding protein AXIN, the tumour 
suppressor adenomatous polyposis coli gene product 
(APC), casein kinase 1 (CK1) and glycogen synthase 3 
(GSK3) [38, 53, 57, 58]. Due to sequential CK1 and 
GSK3 phosphorylation of b-catenin N-terminal 
region, the phosphorylated b-catenin could be re-
cognized by b-TrCP, an E3 ubiquitin ligase subunit 
so that subsequent b-catenin ubiquitination leads 
to its proteasomal degradation (Figure 1 and 2A). 
Continuous elimination of b-catenin prevents it from 
nuclear translocation, and thereby Wnt target genes 
are repressed by the DNA-bound T cell factor/lym-
phoid enhancer factor, belonging to the TCF/LEF 
family of transcriptional factors [54].
Binding of Wnt ligand induces the formation of 
a complex composed of FZD receptor, LRP5/6 co-re-
ceptor and WNT ligand together with the recruitment 
of the scaffolding protein Dishevelled (DVL) [54]. In 
effect, since b-catenin is not degraded, it accumulates 
in the cytoplasm and migrates to nucleus, where it 
forms a complex with TCF/LEF what enables tran-
scription of Wnt target genes [38, 53, 59].
In 2010 Varelas et al. found that activation of the 
Hippo pathway restricts Wnt/b-catenin signalling by in- 
teraction of TAZ and DVL in the cytoplasm (Figure 
2B) [60]. TAZ interaction with DVL inhibits CK1 
binding and Wnt3A-induced DVL phosphorylation, 
thereby inhibiting Wnt3A-induced transcriptional re-
sponse. Loss of TAZ in a cell culture and in the kidneys 
of Taz-null mice results in increased DVL2 phosphoryla- 
tion, enhanced cytoplasmic and nuclear b-catenin 
accumulation and Wnt-target genes’ induction [60]. 
Furthermore, the inhibition of the Hippo pathway 
activity leads to increased nuclear TAZ level so that 
reduced TAZ-DVL binding results in increased target 
gene expression in both pathways (Figure 2B) [60].
Hippo upregulates EGFR/KRAS pathway
Recent reports [50, 61–63] revealed that the Hippo 
pathway effector, YAP1 protein, is involved in the 
regulation of EGFR/KRAS signalling (Figure 3). Dur-
ing homeostasis, degradation of YAP1 is triggered by 
ubiquitin ligase complex substrate recognition factors 
SOCS5/6. It was found that during cancerogenesis 
EGFR-activated Ras, a small GTP-binding protein, 
downregulates SOCS5/6 expression, which increases 
level and half time of YAP1 in the cytoplasm [50]. 
Non-phosphorylated YAP1 may induce transcription 
of EGFR as well as AREG (amphiregulin) genes. Ex-
pression of the EGFR gene leads to up-regulation of 
the above-described positive feedback loop (Figure 3). 
Moreover, amphiregulin proteins (secretory products 
of AREG gene) bind to EGFR and act as autocrine 
growth factors. Such relationship between YAP1 and 
the EGFR pathway was found to be important in the 
progression of oesophageal cancer in patients treated 
with EGFR inhibitors [61]. Recently published results 
of knockdown of YAP1 and knockdown of ERBB3 
study suggested presence of an autocrine loop be-
tween YAP1 and EGFR which may control ovarian 
cell tumourigenesis and cancer progression [63].
The role of the Hippo pathway in intestinal 
epithelial cells
Hippo pathway in intestinal epithelium homeostasis
The inner surface of the intestinal tube is lined with 
a single layer of epithelial cells that play both absorbing 
and secreting functions. Major differentiated cell 
types are enterocytes (which are involved in the up-
take of nutrients), goblet cells (which produce mucus), 
enteroendocrine cells (which produce hormones) and 
Paneth cells. Except for Paneth cells, all cell types 
migrate as clonal lineages to the tip of the villus within 
4–5 days, where they are shed into the lumen [64]. 
Post-mitotic Paneth cells are relatively long-lived (5–6 
weeks) [65] and intermingle with intestinal stem cells 
(ISC) at crypt bottoms to secrete ISC niche factors 
and function in innate immunity. Colon has a simple 
columnar epithelium that lacks Paneth cells; instead, 
so called ‘deep secretory cells’ are thought to be re-
sponsible for the ISC niche function [64, 66]. Regard-
less of the differences in morphology and functions, 
epithelial cell types in intestinal crypts are organized 
into three compartments. All epithelial lining cells are 
derived from intestinal stem cells that occupy the base 
of crypts (1st compartment). ISC divide, migrate and 
start to differentiate into transient-amplifying cells 
in the middle of crypts height (2nd compartment). 
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Transient-amplifying cells finally differentiate into ab-
sorptive cells — enterocytes and secretory cells (goblet 
cells and enteroendocrine cells), which expand from 
the top third part of the crypt and surface epithelium 
to the tip of the villus or colon surface epithelium 
(3rd compartment) [67]. 
The base of intestinal crypts makes a niche for 
ISCs, where two types of stem cells can be found: 
cycling crypt base columnar cells (that cycle asymmet-
rically) and quiescent (+4) cells [68]. Leucine-rich 
repeat-containing GPCR5 (Lgr5) is a marker present 
on the crypt base columnar cells, that are intestinal 
stem cells or long-lived multipotent progenitor cells 
[68, 69]. It has been shown that Lgr5 gene is a down-
stream target of Wnt pathway [69]. Single Lgr5+ stem 
cell can rebuilt an entire crypt-villus-like structure, but 
knock-out (KO) of Lgr5 gene has no detectable effect 
on murine intestinal development, probably since other 
related markers may attain function of the Lgr protein 
[68, 70]. For (+4) quiescent cells there are currently 
no commonly-accepted receptors, however, Bmi1 and 
Musashi-1 have recently been proposed [71, 72]. Bmi1 
expression has been found in distinct cells located near 
the bottom of crypts, which comprise rarely occurring, 
slowly cycling cells located predominantly in the +4 
position [71]. It was shown that Bmi1+ cells in the 
situ ation of conditional Lgr5+ cell deletion, can give 
rise to Lgr+ cells and support crypt-villus regeneration 
[71, 72]. On the basis of these and other findings 
a model in which Lgr5+ cells mediate homeostatic 
self-renewal, whereas Bmi1+ cells mediate injury-in-
duced regeneration has been proposed [73].
Physiological level of Wnt signalling controls the 
rate of a crypt proliferation. The elevated level of Wnt 
signalling is a characteristic feature of ISC in intestinal 
crypts [64] whereas deregulated Wnt signalling can 
lead to colorectal cancer development [64]. R-spon-
din binds to LGR4/LGR5 receptors and enhances 
WNT signals in ISC, but tumour suppressor RNF43 
activity negatively controls WNT signals in ISC by 
ubiquitinating FZD receptors [74, 75]. Furthermore, 
Paneth cells constitutively secrete Wnt3 ligand, but 
the additional source of Wnt proteins also exists in 
the surrounding stromal cells. Notch signalling in the 
intestinal epithelium is involved in inhibition of the 
secretory phenotype of the differentiating ISC [76]. 
The relationships between Hippo pathway and 
Wnt signalling suggest a role of the Hippo pathway 
in the maintenance of the intestinal epithelium ho-
meostasis. The first reports concerning the Hippo 
pathway in intestinal epithelium suggested oncogenic 
role of YAP1. It was demonstrated that endogenous 
YAP1 is expressed in the base of crypts where the 
ISCs reside [77]. In the mouse model, when YAP1 
was activated in a doxycycline-inducible manner, in 
contrast to control mice, cell proliferation upon YAP1 
activation was observed not only in the base of crypts 
but extended through the whole length of crypt’s epi-
thelium [77]. The experimental inhibition of YAP1’s 
activity resumed differentiation of crypts’ epithelial 
cells. Interestingly, YAP1 activation induced intes-
tinal dysplasia and was associated with high level of 
nuclear b-catenin expression, characteristic to active 
Wnt pathway [77].
The role of Hippo pathway in the regeneration  
of intestinal epithelium
The role of YAP1 in tissue regeneration was first de-
scribed in dextran sodium sulphate (DSS)-induced 
colon regeneration model. In normal tissue, YAP1 
protein is present along the entire crypt in both 
types of cells: proliferating and post-mitotic [13]. 
Moreover, conditional YAP1 KO in the intestinal 
epithelium revealed no visible defects in cell dif-
ferentiation, cell death, cell proliferation or cell 
migration along the crypt-villus axis [13]. Five days 
of DSS treatment of wild-type mice resulted in in-
testinal inflammation and slightly decreased YAP1 
protein level. However, two days after DSS with-
drawal, YAP1 protein level dramatically increased. 
Increased YAP1 protein level was observed (by 
immunohistochemistry and WB) in regenerating 
crypts [13]. This study revealed the possibility that 
Hippo signalling may be constitutively activated 
during cell and tissue regeneration, however, 
during normal cell homeostasis YAP1 becomes 
inactivated. Moreover, the inactivation of tumour 
suppressors that normally restrict YAP1 function 
may lead to tumour formation and/or overgrowth 
of intestinal epithelium [13]. E.g., conditional Sav1 
knock-out mice exhibited enlargement of crypts in 
both colon and small intestine with increased num-
ber of proliferating cells. Interestingly this dysplasia 
was completely diminished by loss of YAP1 [13].
The role of MST1 and MST2 kinases in the 
intestinal epithelium was also investigated [13, 78]. 
Ablation of MST1/2 kinases in mouse intestinal 
epithelium caused marked expansion of stem cell 
compartment and loss of secretory cells throughout 
small and large intestine. Decreased phosphoryla-
tion, enhanced abundance and nuclear localization 
of YAP1 were observed as a result of MST1/2 de-
letion in intestinal epithelium with simultaneous 
activation of Wnt and Notch signalling [78]. These 
results correlate with other data obtained upon ac-
tivation of the nuclear form of YAP1 with mutated 
LATS1 phosphorylation site [13], because both of 
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these conditions lead to the Hippo pathway-inde-
pendent activation of YAP1.
Divergent views on the role of YAP1 in intestinal 
tissue regeneration have emerged recently. It has 
been found that in strong cooperation with Wnt 
signalling the Hippo pathway controls the regenera-
tion stage after injury. However, cytoplasmic YAP1 
restricted elevated Wnt signalling independently of 
AXIN-APC-GSK complex, and in some cases acted 
synergistically with the destruction complex to con-
trol the subcellular localization of b-catenin [79]. In 
mouse overexpression of YAP1 gene inhibited the 
Wnt-mediated intestinal regeneration and vice versa 
a loss of YAP1 led to hyperactive Wnt signalling and 
expansion of stem cell niche during regeneration. It 
was found that YAP1 nuclear localization correlated 
with active Wnt signalling whereas its cytoplasmic 
localization inhibited Wnt pathway [79]. 
Control of injury-induced proliferation of cells is 
crucial for maintaining the proper number of cells 
in the regenerating organ. The insufficient prolifer-
ation may lead to atrophy, whereas the dysregulated 
proliferation may lead to tumourigenesis [80]. For 
this reason focusing on mechanisms involved in re-
generation of such organs like intestine, that is per-
manently exposed to potentially injuring factors, may 
provide important clues to the pathomechanisms of 
uncontrolled cellular proliferation that characterizes 
neoplasms, including colorectal cancer (Figure 4).
The role of Hippo pathway  
in colorectal cancer 
Although the most common mutations in CRC involve 
APC gene and dysregulated b-catenin signalling, 
YAP/TAZ can contribute to these mutations [81]. 
Therefore, expression studies of Hippo pathway com-
ponents in CRC have been reported by some groups 
[78, 82–86], however, only Liang et al. presented com-
plex data regarding collaborative expression analysis 
of the most important Hippo genes [87]. They found 
decreased mRNA ratios of LATS1 and MST1/2 as 
well as increased mRNA levels of YAP, TAZ, TEAD 
and OCT4 in CRC in comparison to healthy colon [87]. 
Most of the genes coding for the Hippo pathway 
proteins were shown to function in many types of 
cancer either as tumour suppressors or as oncogenes 
(Table 2). The most commonly focused gene, YAP1, 
was found to be involved in tumour development and 
progression in different malignancies, including CRC. 
Although increased level of the YAP1 protein (as-
sessed by WB) was found in most studies [83, 88–91] 
suggesting its oncogenic role, the under-expression was 
also observed in breast [92] and colorectal cancer [79]. 
The study of Barry et al. showed decreased expression 
of YAP1 in high grade tumours and stage IV [79]. 
The authors suggested that YAP1 is a Wnt target gene 
which plays a role in a negative feedback loop to limit 
Wnt-initiated signals in CRC development [79]. 
This hypothesis sheds a new light on the possible 
role of the Hippo pathway in the Wnt-related patho-
mechanisms of the CRC development. As previously 
mentioned, AXIN destruction complex that contains 
APC protein tightly regulates b-catenin level in Wnt 
pathway (Figure 2A). Common mutations in APC 
gene are found in most CRC cases [81, 93, 94]. These 
mutations lead to an elevated b-catenin level in the 
cell nucleus where it acts as co-activator of transcrip-
tion factors of the TCF/LEF family. The expression 
of the TCF4 transcription factor and the activation 
of Wnt target genes’ transcription by the b-catenin/ 
/TCF4 transcription complex were documented in 
colonocytes [52, 95]. It was proved that b-catenin is 
required for the YAP1 gene expression in HCT116, 
an advanced CRC cell line [95]. YAP1 gene silencing 
in SW620 (colon adenocarcinoma) and HCT116 
(metastatic CRC) cell lines resulted in positive 
regulation of anchorage-independent cell growth, 
because decreased YAP1 level reduced growth of 
colonies in soft agar, especially of SW620 cells. YAP1 
was detected in the cytoplasm of HCT116, SW620, 
SW480, RKO, LS174, and HT29 CRC cell lines, which 
suggests the properly functioning of Hippo pathway 
kinase cassette [95]. Moreover, WB protein analysis 
of nuclear and cytoplasmic fractions from cells grown 
in high confluence revealed that cell density did not 
affect YAP1 nuclear localization [95]. The analysis 
of YAP1/b-catenin expression in primary and meta-
static colorectal tumours revealed that out of the 
36 primary tumours examined, 86% scored positively 
Figure 4. Summary of cellular functions of Hippo pathway 
effector proteins YAP1/TAZ in intestinal epithelium ho-
meostasis and tumourigenesis
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for nuclear localization of b-catenin and YAP1, while 
only 3% lacked nuclear expression of either protein 
[95]. The distribution was comparable in metastatic 
CRC tumours, which suggested that Wnt/b-catenin 
signalling pathway and Hippo/YAP1 pathway con-
verge to promote colon cancer [95].
Expression of Hippo pathway components  
as prognostic factors in colorectal cancer 
Increased expression of YAP1 in CRC was found by 
many groups [13, 46, 78, 96]. E.g., Wang et al. showed 
that YAP was overexpressed in 52.5% (73/139) of 
CRC tumours with a predominant localization in the 
nucleus [97]. Furthermore, YAP1 protein expression 
in CRC patients correlated with cyclin D levels, nodal 
status and pTNM stage. The authors proposed that 
YAP1 may be a prognostic factor in CRC because 
of the correlation between its high expression and 
shorter overall survival [97]. 
Wang et al. also found that YAP1 and TAZ 
expression levels were significantly associated with 
the lymph node status in CRC [82]. It is known from 
other clinical and histopathological studies that have 
been performed for 25 years in a large surgical centre 
that the cut-off values of lymph node ratio are strong 
independent prognostic factors for CRC patients [98]. 
Therefore, high prognostic impact of lymph node 
metastases is a background of the statement regarding 
the role of YAP1 and TAZ in the prognosis of CRC 
patients [82].
Other reports showed the prognostic value of 
YAP1 and TAZ transcription levels for CRC pa-
tients. A positive correlation between TAZ and YAP1 
mRNA expression ratios and their downstream target 
genes AXL and CTGF was found in tumour tissues 
of 522 CRC patients [85]. In the same study it was 
demonstrated that TAZ, but not YAP mRNA level 
can be used to predict survival of CRC patients [85]. 
Increased TAZ mRNA level may not necessarily cor-
relate with the increase of its transcriptional activity 
since post-translational modifications like phospho-
rylation may cause its cytoplasmic sequestration. 
Therefore Yuen et al. proposed to associate TAZ 
expression with the expression of its two downstream 
genes, AXL and CTGF. Patients whose tumours 
overexpressed one, two or all of the three genes had 
an increasing risk for disease progression [85]. Based 
on microarray technique, it was also shown that target 
genes involved in EMT, migration and invasion, colon 
cancer progression, cancer signalling, angiogenesis 
and others factors engaged in tumourigenesis, pre-
sented differences in their expression level between 
high and low grade CRC patients which correlated 
with TAZ-AXL-CTGF expression [85]. Two poten-
tial therapeutic targets, ANO1 and SQLE, were also 
identified: in patients with upregulated TAZ-AXL-
CTGF expression, a decrease in expression of either 
ANO1 and SQLE or both genes was associated with 
the survival of TAZ-AXL-CTGF high grade colon 
cancer patients [85]. Although the identification of 
EMT markers can serve as potential prognostic CRC 
factors, the most recent data suggest caution when 
interpreting large scale transcriptome data from 
cancer due to contamination of tumour samples with 
stromal cells [99].
In a quantitative PCR study which focused on the 
expression of all Hippo elements in CRC, the mRNA 
levels of MST1 and LATS2 were decreased to higher 
extent in colorectal cancer tissues than in colorectal 
adenomas or adjacent non-tumour tissues (non-tu-
mour tissues > adenomas > cancer) [87]. The mRNA 
expression levels of YAP, TAZ and TEAD1 increased 
in colorectal cancer compared to colorectal adeno-
mas and non-tumour tissues (cancer > adenomas > 
non-tumour tissues). Similar results were obtained on 
protein level by WB analysis. The clinicopathologic 
analysis revealed that expression levels of MST1, 
LATS2 and CDX2 (Caudal type homeobox tran-
scription factor2, marker of throphoectoderm which 
plays important roles in endoderm and intestinal 
development) in patients with lymph node metastasis 
were significantly lower than those in patients without 
lymph node metastasis. Finally the mRNA levels of 
MST1, LATS2 and CDX2 gradually decreased with 
the TNM stage (I > II > III > IV) and the mRNA 
levels of YAP1, TAZ and TEAD1 gradually increased 
with TNM (IV > III > II > I) [87]. 
Associations of Hippo pathway  
with therapeutic strategies in CRC
Personalized therapy of advanced cancer was applied 
as a result of molecular progress in cancer cell biology. 
Another important reason for personalized therapy 
in CRC was the occurrence of chemoresistance of tu-
mour cells in some patients when the traditional drug, 
5-fluorouracil (5FU) was introduced in metastatic 
CRC therapy [100]. Recent reports on HT29 CRC 
cell line revealed high level of YAP in 5FU resistant 
cells. It was found that after exposing the cells to 5FU 
YAP became localized in cytoplasmic compartment 
of cells and phosphorylated causing the cells to enter 
quiescence. Increased YAP protein levels were also 
seen in human CRC liver metastases and were cor-
related with CRC relapse [43, 101]. 
The recently introduced biological drugs act 
directly on specific cellular targets, mainly growth 
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factor receptors. Chemotherapy based on modern 
molecular-targeting drugs like Cetuximab, Regorafenib 
or Panitumumab (humanized monoclonal antibodies 
against EGFR, CEGFR2-TIE2 and EGFR, respec-
tively) showed some efficacy in advanced CRC, but 
there is only scarce data regarding targeted CRC 
therapy in respect to the Hippo pathway.
Lee et al. assessed the possible connection between 
cetuximab-treated CRC patients and YAP1 mRNA 
expression; patients with CRC were divided into 
two groups: one group with activated YAP1 in CRC 
(AYCC) and the second one with inactivated YAP1 in 
colorectal cancer (IYCC). Statistical analysis revealed 
that patients with AYCC had slightly more advanced 
disease than had patients with IYCC (but patients 
with stage IV were excluded from this analysis). In the 
group of patients with stage I–III, the AYCC patients 
demonstrated much shorter survival rates than IYCC 
patients [102]. During analysis of all tumour stages 
patients (n = 80) who received cetuximab monother-
apy, it was found that only in IYCC patients tumour 
shrinkage (complete or partial remission) occurred. 
YAP1 activation was significantly associated with 
poor response to cetuximab therapy in colorectal can- 
cer [102]. Although more studies are necessary, it 
appears that similarly as in head and neck cancer in 
which YAP1 is a potential marker for cetuximab re-
sistance [103], YAP1 expression in colorectal cancer 
could be regarded as a potential marker of cetuximab 
therapy effectiveness. 
Recently, the association of the EGFR/KRAS 
pathway with YAP1 expression has been observed 
in drug-resistant oesophageal cancer [61]. Since 
the presence of drug-resistant CRC emerged as an 
important clinical problem [6, 104], we propose that 
a possible association of the YAP1 expression with 
the EGFR signalling pathway in CRC should be also 
studied.
Conclusions
The Hippo pathway is an evolutionary conserved regu-
lator of cell proliferation, death and differentiation. 
It controls organ size and tissue homeostasis and acts 
mainly through inhibition of the activity of YAP1 and 
TAZ kinases, its major nuclear effectors. The activity 
of the Hippo pathway can be modulated by cross talk 
with other signalling pathways such as Wnt or EGFR/ 
/KRAS which are important in the control of intestinal 
epithelium’s homeostasis. In the intestine, inhibition 
of the Hippo pathway activity results in stem cell 
expansion and neoplastic growth. Although core com-
ponents and their influence on key nuclear effectors 
are well established, mechanisms that de-regulate the 
Hippo pathway, are poorly understood. The available 
experimental and clinical data strongly suggest that 
the role of the Hippo pathway should be further ex-
plored under different pathological conditions such as 
cell/tissue injury or neoplastic transformation of intes-
tinal epithelium. Moreover, the possible involvement 
of the Hippo pathway components in drug resistance 
of advanced CRC should also be investigated. 
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